Armata Pharmaceuticals, Inc. (FRA:TG1N)
Germany · Delayed Price · Currency is EUR | Market Cap | 246.35M +443.8% |
| Revenue (ttm) | 4.51M +10.7% |
| Net Income | -245.11M |
| EPS | -6.75 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.75 |
| Previous Close | 6.70 |
| Day's Range | 6.45 - 6.75 |
| 52-Week Range | 1.48 - 12.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc. [Read more]
Financial Performance
In 2025, Armata Pharmaceuticals's revenue was $4.90 million, a decrease of -5.22% compared to the previous year's $5.17 million. Losses were -$173.80 million, 818.8% more than in 2024.
Financial numbers in USD Financial StatementsNews
Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year
Reports Q1 revenue $0.8M vs. $0.5M last year. “Our top priority in 2026 is advancing Armata’s lead Staphylococcus aureus therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in…
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Comp...
Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted Fast Track Designation to AP-SA02, the company’s intravenously administered Staphylococcus aureus multi-phage product candidate, f...
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 ...
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm...
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.
LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi...
Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch
JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on Armata Pharmaceuticals (ARMP) to $20 from $15 and keeps a Buy rating on the shares. After speaking with key opinion…
Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year
The company recognized grant revenue of $1.1M for the three months ended December 31, 2025 as compared to $1.2M in the comparable period in 2024, which represents MTEC’s share of…
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi...
Armata Pharmaceuticals delays announcement of Q4, FY25 results
Armata Pharmaceuticals (ARMP) announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025. The Company requires additional time ...
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi...
Armata price target raised to $15 from $9 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Armata Pharmaceuticals (ARMP) to $15 from $9 and keeps a Buy rating on the shares after the company announced that AP-SA02 received…
Armata Pharmaceuticals receives FDA QIDP designation for AP-SA02
Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted AP-SA02, the company’s Staphylococcus aureus multi-phage product candidate, for intravenous use as a Qualified Infectious Disease ...
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity and the potential for fast tra...
Armata Pharmaceuticals announces End-of-Phase 2 meeting with FDA
Armata Pharmaceuticals (ARMP) announced the conclusion of an End-of-Phase 2 written response from the U.S. FDA and plans to advance the company’s intravenously-administered Staphylococcus aureus bacte...
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES, Jan. 13, 2026 /...
Armata Pharmaceuticals initiated with a Buy at JonesResearch
JonesResearch analyst Debanjana Chatterjee initiated coverage of Armata Pharmaceuticals (ARMP) with a Buy rating and $15 price target What differentiates Armata from other companies developing clinica...
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
LOS ANGELES , Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu...
Armata Pharmaceuticals reports Q3 EPS (74c) vs. (15c) last year
Reports Q3 revenue $1.2M vs. $3.0M last year. As of September 30, Armata held approximately $14.8M of unrestricted cash and cash equivalents, vs. $9.3M as of December 31, 2024. “Compelling…
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu...
Armata Pharmaceuticals trading resumes
10:10 EST Armata Pharmaceuticals (ARMP) trading resumes
Armata Pharmaceuticals trading halted, volatility trading pause
10:05 EST Armata Pharmaceuticals (ARMP) trading halted, volatility trading pause
Armata announces comissioning of cGMP manufacturing facility in Los Angeles
Armata Pharmaceuticals (ARMP) announced that its state-of-the-art current Good Manufacturing Practice, or cGMP, manufacturing facility in Los Angeles, California, has been formally commissioned. As pa...
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
LOS ANGELES , Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu...
Here’s Why Armata Pharmaceuticals Stock (ARMP) Exploded 300% Today
Armata Pharmaceuticals ($ARMP) stock exploded nearly 300% on Wednesday after the biotech firm released encouraging mid-stage trial data for its experimental antibacterial therapy, AP-SA02. The treatme...